{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-062027","form_type":"8-K","ticker":"BOLT","cik":"0001641281","company_name":"Bolt Biotherapeutics, Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.908530+00:00","generated_at":"2026-06-08T06:50:28.482724+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Bolt Biotherapeutics Q3 2023: cash $141.4M, BDC-1001 29% ORR, BDC-3042 dosed","bullets":["Cash, cash equivalents and marketable securities of $141.4M as of Sept 30, 2023; expected to fund operations through 2025.","Collaboration revenue $2.5M (vs $2.1M Q3 2022); R&D expenses $15.0M (down from $19.0M).","Loss from operations of $18.2M vs $22.3M in prior year quarter.","BDC-1001 Phase 1 updated data: 29% ORR monotherapy; first complete response; well tolerated; Orphan Drug Designation for gastric cancers.","First patient dosed with BDC-3042 in Phase 1/2 for advanced solid tumors."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-062027","json":"https://secwatch.observer/filing/0000950170-23-062027.json","markdown":"https://secwatch.observer/filing/0000950170-23-062027.md","text":"https://secwatch.observer/filing/0000950170-23-062027.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1641281/000095017023062027/0000950170-23-062027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1641281/000095017023062027/bolt-20231109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T06:50:28.482724+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e88f2957458f8c0a093c25e4f66dae0aae4d0090","claim":"Bolt Biotherapeutics, Inc. reported the third quarter ended September 30, 2023 results: revenue $2.5 million.","evidence_excerpt":"2023. Cash on hand is expected to fund multiple milestones and operations through 2025. Third Quarter 2023 Financial Results • Collaboration Revenue – Collaboration revenue was $2.5 million for the quarter ended September 30, 2023, compared to $2.1 million for the same quarter in 2022. Revenue in the comparative periods were generated from the services performed","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1641281/000095017023062027/0000950170-23-062027-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Revenue","value":"$2.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}